These new compounds are being tailored to optimize efficacy, safety, and pharmacokinetic profiles, targeting critical unmet needs in oncology, including central nervous system (CNS) malignancies.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Mora's promotion at WLS aims to improve customer support and optimize labeling equipment performance over time.

LPAI causes only mild symptoms, is slower to spread and has lower mortality than highly pathogenic avian influenza (HPAI).

The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...

Maven Clinic, the world's largest virtual clinic for women's and family health, today released its fourth annual State ...

Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...

Health insurance companies are potentially making billions in additional profits from drug copay assistance programs while denying patients some of the benefits they were designed to provide. (Igor ...

This platform enables scientists to mine large-scale data, advance AI drug discovery, and optimize drug design. By integrating AI and machine learning into the R&D process, the company aims to ...

(TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program.